EMA Endorses Theriva Biologics’ Phase 3 VCN-01 Trial Design for Metastatic Pancreatic Cancer—Path Cleared for Innovative Approach
Market Chameleon (Mon, 29-Dec 10:32 AM)
Why Is Theriva Biologics Stock Gaining Monday?
at www.benzinga.com (Mon, 29-Dec 11:41 AM)
Theriva Biologics Gains EMA Backing for VCN-01 Phase 3
at www.tipranks.com (Mon, 29-Dec 8:33 AM)
